Canada markets closed

NOXXON Pharma N.V. (ALNOX.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
0.0566+0.0016 (+2.91%)
At close: 05:35PM CEST
Full screen
Loading interactive chart...
  • Business Wire

    Noxxon Provides Results of Its 2022 Annual General Meeting of Shareholders

    BERLIN, June 29, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today the results of its 2022 annual general meeting of shareholders (AGM), which took place on June 29, 2022, at 02.00 p.m. CEST. Shareholders representing a total of 9.33% of the total issued and outstanding share capital on June 1, 2022, were represented in person or by p

  • Business Wire

    NOXXON Announces Corporate Action to Start the Parity Period

    BERLIN, June 23, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announces the start of the parity period on June 27, 2022, following the approval of share consolidation at the extraordinary general meeting of shareholders (EGM) on May 16, 2022.

  • Business Wire

    NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observed With NOX-A12 in Combination With Radiotherapy and Bevacizumab in Brain Cancer

    BERLIN, June 23, 2022--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today an updated strategy to focus its capabilities on NOX-A12 in brain cancer (glioblastoma) and in particular on the triple combination of NOX-A12, radiotherapy and bevacizumab. This decision follows positive data generated in the GLORIA Phase 1/2 study, consisting of a dose-escalation